Constantine Milathianakis

417 total citations
18 papers, 334 citations indexed

About

Constantine Milathianakis is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Constantine Milathianakis has authored 18 papers receiving a total of 334 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 3 papers in Surgery. Recurrent topics in Constantine Milathianakis's work include Prostate Cancer Treatment and Research (11 papers), Bone health and treatments (7 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). Constantine Milathianakis is often cited by papers focused on Prostate Cancer Treatment and Research (11 papers), Bone health and treatments (7 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). Constantine Milathianakis collaborates with scholars based in Greece, United States and Spain. Constantine Milathianakis's co-authors include John Bogdanos, Dimitrios Karamanolakis, Constantine S. Mitsiades, Michael Koutsilieris, Antigone Sourla, Peter Lembessis, Ρωξάνη Τέντα, Antonis Halapas, Nikolaos Pissimissis and Théodoros Dimopoulos and has published in prestigious journals such as Clinical Cancer Research, Annals of Oncology and British Journal of Urology.

In The Last Decade

Constantine Milathianakis

17 papers receiving 328 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Constantine Milathianakis Greece 12 175 134 83 75 65 18 334
John Bogdanos Greece 12 147 0.8× 118 0.9× 71 0.9× 74 1.0× 48 0.7× 15 319
María Ángeles Vaz Salgado Spain 9 101 0.6× 125 0.9× 81 1.0× 101 1.3× 62 1.0× 44 354
J. Morreau Netherlands 5 87 0.5× 194 1.4× 47 0.6× 40 0.5× 59 0.9× 7 296
Michael Koutsilieris Greece 9 84 0.5× 97 0.7× 97 1.2× 63 0.8× 45 0.7× 21 308
R. Ben Yosef Israel 6 147 0.8× 139 1.0× 114 1.4× 85 1.1× 19 0.3× 11 369
Bisong Haupt United States 11 85 0.5× 201 1.5× 69 0.8× 32 0.4× 58 0.9× 11 386
Birthe Heitkötter Germany 9 178 1.0× 103 0.8× 50 0.6× 36 0.5× 28 0.4× 18 323
Tomoki Yokoyama Japan 11 227 1.3× 196 1.5× 139 1.7× 102 1.4× 63 1.0× 19 535
Klaus-Peter Kuenkele Germany 3 152 0.9× 95 0.7× 135 1.6× 116 1.5× 72 1.1× 5 353
Thomas C. Putti Singapore 12 90 0.5× 140 1.0× 80 1.0× 30 0.4× 61 0.9× 16 367

Countries citing papers authored by Constantine Milathianakis

Since Specialization
Citations

This map shows the geographic impact of Constantine Milathianakis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Constantine Milathianakis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Constantine Milathianakis more than expected).

Fields of papers citing papers by Constantine Milathianakis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Constantine Milathianakis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Constantine Milathianakis. The network helps show where Constantine Milathianakis may publish in the future.

Co-authorship network of co-authors of Constantine Milathianakis

This figure shows the co-authorship network connecting the top 25 collaborators of Constantine Milathianakis. A scholar is included among the top collaborators of Constantine Milathianakis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Constantine Milathianakis. Constantine Milathianakis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Karamanolakis, Dimitrios, et al.. (2012). New strategies for the treatment of hormone-independent prostate cancer.. PubMed. 7(2). 107–12.
2.
3.
Koutsilieris, Michael, Constantine Milathianakis, John Bogdanos, et al.. (2007). Combination of somatostatin analogues and dexamethasone (antisurvival‐factor concept) with luteinizing hormone‐releasing hormone in androgen ablation‐refractory prostate cancer with bone metastasis. British Journal of Urology. 100(s2). 60–62. 12 indexed citations
4.
Koutsilieris, Michael, John Bogdanos, Constantine Milathianakis, et al.. (2006). Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach. Expert Opinion on Investigational Drugs. 15(7). 795–804. 13 indexed citations
5.
Karamanolakis, Dimitrios, John Bogdanos, Constantine Milathianakis, et al.. (2006). Serum testosterone: A potentially adjunct screening test for the assessment of the risk of prostate cancer among men with modestly elevated PSA values (> or =3.0 and <10.0 ng/ml).. PubMed. 26(4B). 3159–66. 25 indexed citations
6.
Mitsiades, Constantine S., et al.. (2006). Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer.. PubMed. 26(5B). 3693–700. 30 indexed citations
7.
Koutsilieris, M., C Mitsiades, John Bogdanos, et al.. (2006). RANDOMISED CONTROLLED CLINICAL TRIAL OF A COMBINATION OF SOMATOSTATIN ANALOG AND DEXAMETHASONE PLUS ZOLEDRONATE VS. ZOLEDRONATE IN PATIENTS WITH ANDROGEN ABLATION REFRACTORY PROSTATE CANCER. European Urology Supplements. 5(2). 93–93. 8 indexed citations
8.
Milathianakis, Constantine, John Bogdanos, & Dimitrios Karamanolakis. (2005). Morbidity of prophylactic inguinal lymphadenectomy with saphenous vein preservation for squamous cell penile carcinoma. International Journal of Urology. 12(8). 776–778. 18 indexed citations
9.
Milathianakis, Constantine, et al.. (2005). [Vaginal metastases from renal cell carcinoma].. PubMed. 15(2). 319–21. 4 indexed citations
10.
Mitsiades, Constantine S., Peter Lembessis, Antigone Sourla, & Constantine Milathianakis. (2004). Molecular staging by RT-PCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer. Clinical & Experimental Metastasis. 21(6). 495–505. 43 indexed citations
11.
Koutsilieris, Michael, et al.. (2004). Combination of Somatostatin Analog, Dexamethasone, and Standard Androgen Ablation Therapy in Stage D3 Prostate Cancer Patients with Bone Metastases. Clinical Cancer Research. 10(13). 4398–4405. 39 indexed citations
12.
Bogdanos, John, Dimitrios Karamanolakis, Ρωξάνη Τέντα, et al.. (2003). Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton.. Endocrine Related Cancer. 10(2). 279–289. 58 indexed citations
13.
Bogdanos, John, et al.. (2003). Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement.. PubMed. 23(2C). 1757–62. 19 indexed citations
14.
Bogdanos, John, Dimitrios Karamanolakis, Constantine Milathianakis, & Michael Koutsilieris. (2003). Syndrome of inappropriate antidiuretic hormone secretion in a patient with hormone refractory prostate cancer.. PubMed. 23(2C). 1755–6. 4 indexed citations
15.
Koutsilieris, Michael, Dimitrios Karamanolakis, John Bogdanos, et al.. (2002). Combination of dexamethasone and a somatostatin analogue in the treatment of advanced prostate cancer. Expert Opinion on Investigational Drugs. 11(2). 283–293. 18 indexed citations
16.
Karamanolakis, Dimitrios, John Bogdanos, Antigone Sourla, et al.. (2002). Molecular Evidence-Based Use of Bone Resorption-Targeted Therapy in Prostate Cancer Patients at High Risk for Bone Involvement. Molecular Medicine. 8(11). 667–675. 11 indexed citations
17.
Kosmidis, P., C. Bacoyiannis, George Fountzilas, et al.. (1997). 5-Fluorouracil, interferon-α-2b and cisplatin (FAP) for advanced urothelial cancer. A phase II study. Annals of Oncology. 8(4). 373–378. 9 indexed citations
18.
Milathianakis, Constantine, et al.. (1986). Radioisotopic evaluation of adenocarcinoma and solitary cyst of the kidney.. PubMed. 54(1). 5–18. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John Bogdanos Breakdown of academic impact, for papers by María Ángeles Vaz Salgado Breakdown of academic impact, for papers by J. Morreau Breakdown of academic impact, for papers by Michael Koutsilieris Breakdown of academic impact, for papers by R. Ben Yosef Breakdown of academic impact, for papers by Bisong Haupt Breakdown of academic impact, for papers by Birthe Heitkötter Breakdown of academic impact, for papers by Tomoki Yokoyama Breakdown of academic impact, for papers by Klaus-Peter Kuenkele Breakdown of academic impact, for papers by Thomas C. Putti
Rankless by CCL
2026